What Фуциталмик treats: main uses and benefits

Фуциталмик is an ophthalmic preparation that is indicated for the topical treatment of bacterial eye infections. The medication is designed to support the resolution of infections where the organism is sensitive to the antibiotic ingredient. Clinical use typically addresses conditions such as acute bacterial conjunctivitis (red eye), blepharitis (inflammation of the eyelids), and hordeolum (stye).

This treatment functions by working to help address the bacterial cause of the infection, which in turn helps minimize associated symptoms like redness, discharge, and irritation. It is also used in managing other superficial eye infections. The selection of this medication should be guided by a healthcare professional to ensure it is appropriate for the condition being treated.

---

Quick Fact: Relief for Eye Irritation and Discharge

Regulatory References

1. Health Canada therapeutic overview for fusidic acid

Eligibility Map: Who can and cannot use Фуциталмик — official regulatory information

Scope Item	Official Regulatory Statement
Populations for whom use is allowed	Adults and children aged two years and older are eligible for use under standard conditions.
Populations for whom use is contraindicated	The medicine is contraindicated in patients with known hypersensitivity or allergy to the active ingredient, fusidic acid, or any of the other components, including the preservative benzalkonium chloride.
Age-related eligibility rules	Efficacy and safety have not been established for use in children under two years of age. Additionally, the medicine is not recommended for the treatment of neonatal conjunctivitis.
Condition-specific eligibility rules	No specific limitations are documented for patients with renal or hepatic impairment, as systemic absorption following topical application is negligible.
Pregnancy and lactation eligibility status	Use is classified as permissible. No effects are anticipated during pregnancy or breastfeeding, as the systemic exposure is negligible.
Eligibility-related restrictions	Individuals who wear soft contact lenses must remove them before application, as the excipient benzalkonium chloride may cause lens discoloration. Use requires caution in patients with a compromised cornea or dry eyes.

---

Eligibility classifications (high-level)

Classification Item	Regulatory Terminology / Context
Eligibility severity classification	Contraindicated (Hypersensitivity), Not Established (Children under 2 years), Permissible (Pregnancy/Lactation), Caution (Compromised Cornea).
Regulatory basis	Based on official documents, including the Summary of Product Characteristics (SmPC) and Product Monographs.
Eligibility-context constraints	Constraints are primarily tied to local hypersensitivity reactions and the effect of the benzalkonium chloride excipient on contact lenses and the corneal surface.

---

Resulting eligibility structure

Official eligibility statements:

• The medicine is formally contraindicated in individuals with a history of allergy to fusidic acid or the excipient benzalkonium chloride.
• The regulatory profile for children under two years of age specifies that the efficacy of the product has not been established.
• The lack of significant systemic exposure allows the medicine to be classified as generally permissible for individuals who are pregnant or breastfeeding.
• Patients who wear soft contact lenses are subject to the restriction of removing the lenses prior to application due to the excipient.

Connection to the overall eligibility profile (2–4 sentences): The regulatory profile is primarily determined by two factors: hypersensitivity to the drug or excipients, which constitutes the absolute exclusion criteria for all populations, and the negligible systemic absorption of the topical formulation. This minimal absorption allows the medicine to be generally permissible for use during pregnancy, lactation, and in patients with underlying hepatic or renal conditions. Specific limitations apply only to the pediatric group under two years of age, where efficacy is not established.

Interactions with other medicines and products

The active ingredient in Fucithalmic (fusidic acid) viscous eye drops is associated with a highly limited interaction profile due to its formulation. Systemic interactions are considered unlikely because systemic exposure following topical ophthalmic application is negligible and no specific interaction studies with other medicines have been performed.

---

Documented Interaction Constraints

The interaction profile primarily addresses local, non-drug product compatibility and administration timing with other eye preparations.

Interaction Type	Requirement and Constraint
Soft Contact Lenses (Non-Drug Product)	Lenses must not be worn during treatment. The microcrystalline active ingredient may cause scratches to the cornea or contact lens. The preservative, benzalkonium chloride, may also cause discolouration of soft contact lenses.
Other Ophthalmic Preparations	If using other types of eye drops or ointments, they should be applied with a time interval of at least 5 to 10 minutes to avoid washing out or dilution of Fucithalmic.
Systemic Medicines (Oral/Injectable)	No documented interactions. Official labeling states systemic exposure is negligible, rendering interactions with medicines processed by hepatic enzymes (e.g., CYP) or drug transporters highly improbable.

---

Summary

The regulatory-based interaction profile for Fucithalmic focuses exclusively on local constraints, requiring the removal of contact lenses and a mandatory time separation when co-administering other topical eye medications. There are no documented interaction concerns with oral or injected medicines.

How Фуциталмик Works

The mechanism of action for Фуциталмик (fusidic acid) involves its effect on bacterial protein synthesis. This action is achieved by targeting the elongation factor G (EF-G) , a critical element in the ribosome's function.

---

Inhibition of Protein Translation

The drug acts by binding directly to the elongation factor G (EF-G) complexed with guanosine diphosphate (GDP) on the bacterial ribosome. This binding prevents the dissociation of the EF-G/GDP complex following the hydrolysis of guanosine triphosphate (GTP), thereby arresting the translocation step of the peptidyl-tRNA. This disruption effectively stalls the ribosome's ability to move along the messenger RNA (mRNA) strand and continue adding amino acids to the growing peptide chain.

---

Disruption of Cellular Growth

This molecular arrest of protein translocation halts the synthesis of essential structural and enzymatic proteins required for bacterial cell function. The resulting cellular consequence is a bacteriostatic effect, which is characterized by the cessation of bacterial cell proliferation, preventing an increase in the bacterial population.

Application Process

The application of this viscous eye drop formulation requires careful handling to ensure the product remains uncontaminated and is delivered effectively to the ocular surface. Before beginning the process, hands should be thoroughly washed with soap and water.

Administration Steps

When applying the eye drops, the head is typically tilted back while looking upward. The lower eyelid is gently pulled down to create a small pocket. The tube is held above the eye without allowing the tip to touch the eye, eyelid, eyelashes, or any other surface. A single drop is then squeezed into the pocket formed by the lower lid.

After application, the eye should be closed for a brief period. During this time, gentle pressure can be applied to the inner corner of the eye (near the nose) to help keep the medication on the ocular surface and minimize systemic absorption. If the medication is being used in both eyes, the process is repeated for the second eye.

Handling and Storage

To maintain the integrity of the product, the cap must be replaced tightly immediately after each use. The tip of the tube is designed for precision and must be kept clean; contact with any surface can introduce bacteria into the medication. If the product appears cloudy or changed in color, its use should be discontinued.

Contact Lens Considerations

In general, the use of contact lenses is discouraged during the course of treatment for eye infections, as the lenses can trap microorganisms or react with the components of the eye drops. If lens wear is necessary, they are typically removed before application and should not be reinserted for a specific duration as advised by a healthcare professional.

Research Evidence / Overview of Studies for Фуциталмик

---

Evidence for Use in Acute Bacterial Conjunctivitis

The primary research for Фуциталмик has focused on its evaluation in cases of acute bacterial conjunctivitis, a condition characterized by periods of heightened symptoms such as redness and discharge. The available evidence base includes many Randomized Controlled Trials (RCTs) and Systematic Reviews that consolidate the findings of these studies. Research has explored the medicine’s evaluation against both suspected and laboratory-confirmed infections.

In these studies, researchers monitored patient outcomes related to physical discomfort. They measured the Clinical Cure/Recovery Rate, which assessed how symptoms evolved in the observed populations, and the Microbiological Eradication Rate, which tracked the microbiological eradication of the targeted bacteria. Findings describe patterns observed in the studies when the medication was compared against an inactive substance (placebo) and against other ophthalmic antibiotics that were evaluated in the trials.

It is important to understand that research highlights changes measured during the study period, but there is limited information for long-term clinical outcomes and the rate of infection recurrence after the short follow-up periods. Researchers have noted the complexity in interpreting some findings due to the high rate of spontaneous resolution of this condition; many cases of conjunctivitis naturally improve on their own, even without treatment. Furthermore, studies generally focus on bacteria susceptible to the medicine’s activity; comparative evidence against a broader range of pathogens is limited.

---

Evidence for Use in Superficial Ocular Adnexal Infections

Research has also explored the evaluation of this medicine in conditions involving temporary physiological imbalance in the eye's surrounding structures, such as chronic blepharitis (inflammation of the eyelids). The studies conducted for this category include a smaller number of Randomized Controlled Trials (RCTs). Research explored short-term symptom changes and evaluated the medicine in the context of trials for these types of conditions.

In these trials, outcomes linked to inflammatory or irritative states were monitored. Studies reported measurements of symptom change, such as the resolution of visible inflammation and crusting on the eyelids. Data for these specific chronic conditions remain insufficient compared to the body of evidence for acute conjunctivitis. Follow-up durations were limited in many studies, meaning long-term effects are not fully established for managing chronic or recurring infections like blepharitis.

---

Understanding Evidence Gaps and Research Uncertainty

The research provides context for the evaluation of Фуциталмик, but it does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted. Evidence highlights what is known—and what is still uncertain—about this medicine. A key uncertainty noted by researchers relates to separating the medicine’s effect from the natural healing process, since many of the conditions studied are self-limiting. The evidence quality varies across studies, and some older trials were assessed as having an unclear or high risk of bias, which can affect the certainty of the findings. Overall, comparative evidence is lacking against a complete range of available treatments, and long-term effects for managing chronic conditions are not fully established.

Key Studies & References

1. Fucithalmic (Fusidic Acid) Product Monograph (Regulatory Overview)
2. Fusidic acid ophthalmic preparations in the management of bacterial eye infections (Drug and Therapeutics Bulletin summary of evidence)

Common questions about Фуциталмик (FAQ)

---

Q: What is the main purpose of Фуциталмик eye drops?

Official product information states that this medicine is indicated for the topical treatment of bacterial conjunctivitis and other superficial eye infections. It is used specifically for conditions that are caused by bacteria known to be susceptible to its active ingredient, fusidic acid.

---

Q: Is Фуциталмик a steroid, or is it an antibiotic?

Фуциталмик contains the active ingredient fusidic acid, which is classified as an antibiotic. Although it has a chemical structure similar to some steroids, official documents clarify that it does not exhibit any steroid-like pharmacological activity.

---

Q: How quickly can I expect to see an improvement in my symptoms after starting Фуциталмик?

Regulatory information indicates the medicine is formulated for twice-daily application to ensure consistent antibiotic levels are maintained in the eye. Clinical success (symptom relief) in studies is often evaluated after a short course of treatment, typically around seven days. The rate of initial improvement may vary between individuals.

---

Q: Why is it important to keep using the drops for 48 hours after the eye looks normal?

Official directions specify the need to continue treatment for at least 48 hours after the signs of infection have resolved. Official documents describe this practice as important because it is intended to help reduce the risk of the infection returning (relapse) after visible symptoms have gone.

---

Q: Can a second eye infection happen if I use the drops for too long?

Regulatory documents advise that avoiding extended or recurrent use is important. This is because prolonged use can increase the documented risks of developing antibiotic resistance or a superinfection, which is defined as a secondary infection, potentially by non-susceptible organisms, including fungi.

---

Q: What is the white powder I see around my eye after applying the drops?

According to the Patient Information Leaflet, observing a white powder or crusting around the eye after the drops dry out is a common occurrence. The Patient Information Leaflet describes this as a normal observation related to the medicine's formulation and viscosity.

---

Q: What should I do if the irritation or stinging in my eye does not go away?

While minor stinging or burning is a common side effect, if irritation, stinging, or any other adverse reaction persists or worsens, official documents advise that persistent adverse reactions or signs of a serious allergic reaction, such as swelling of the face, should be reported to a healthcare provider.

---

Q: Can I use Фуциталмик to treat eye conditions other than those it was prescribed for?

Official labeling states the medicine is intended only for its approved indications and should not be used to treat other eye complaints. The medication is only indicated for superficial bacterial eye infections caused by susceptible pathogens.

---

Q: What are the ingredients in the eye drops besides the active antibiotic?

The active ingredient is fusidic acid. The formulation also contains several excipients (inactive ingredients), which include the preservative benzalkonium chloride, disodium edetate, mannitol, carbomer, sodium hydroxide, and water for injections.

---

Q: Can I drink alcohol while I am using these eye drops?

Official product information indicates that because the medicine is applied topically to the eye and has negligible systemic exposure, interactions with alcohol are not anticipated.

---

Q: Are there specific types of bacteria that are known to be resistant to Фуциталмик?

Studies and regulatory documents indicate that the medicine is generally active against many Gram-positive bacteria, like Staphylococcus aureus. However, some bacteria, particularly those found in the gut or environment, such as Enterobacteriaciae and Pseudomonas aeruginosa, are officially noted to be resistant to the effects of fusidic acid.

---

Q: What is the difference between the single-dose dropper and the multi-dose tube?

The primary difference between the two container types is the presence of a preservative. Multi-dose tubes contain the excipient benzalkonium chloride, while official documents note that unpreserved unit-dose preparations may be made available for patients who have known hypersensitivity to the preservative.

---

Q: Does this medicine treat viral eye infections like cold sores?

No. This medicine is an antibiotic specifically indicated for treating bacterial eye infections. Official product labeling specifies that this medicine is intended for bacterial infections only and is not intended to address conditions, such as viral or fungal infections, that are not caused by susceptible bacteria.

---

Q: What should I do if I accidentally touch the tip of the tube to my eye?

Official instructions warn against touching the tip of the tube to prevent contamination of the product. The tube has a mandated discard date of 28 days after first opening, which helps maintain sterility. If contamination occurs, the potential for reduced quality must be considered against this limit.

---

Q: Can I use the drops if the color or consistency in the tube has changed?

Official product information requires discarding the tube after 28 days of its first opening. Furthermore, the medicine is not intended for use if the seal is broken or if there are noticeable changes in the product's physical appearance or consistency.

---

Q: Are there specific strains of bacteria that are not killed by the medication?

Official documents indicate that the medicine's activity is primarily focused on Gram-positive bacteria. Strains such as Enterobacteriaciae and Pseudomonas aeruginosa are officially noted to be non-susceptible or resistant to the effects of fusidic acid.

---

Q: Can I use it for an infection in both eyes, even if only one eye is showing symptoms?

Official guidance notes that while a patient may have symptoms in only one eye, the treatment regimen may include applying the drops to both eyes. This approach is described as being used to help prevent the potential spread of the infection.

---

Q: What are the common symptoms of the eye infections that Фуциталмик is intended to treat?

This medicine is used for conditions like acute bacterial conjunctivitis, which is associated with common symptoms such as redness, discharge, burning, stinging, and itchiness. In studies, symptoms such as discharge and redness are tracked as part of assessing the medicine’s activity.

---

Q: What is the difference between a clinical cure and a microbial cure in studies of this medicine?

In research, the Clinical Cure rate refers to the resolution or significant improvement of the visible symptoms and signs of the infection, such as discharge and redness. The Microbiological Cure rate, in contrast, refers to the confirmed killing or eradication of the targeted bacteria.

How to Store and Dispose of Fucithalmic

Fucithalmic (fusidic acid) viscous eye drops must be stored and handled according to official regulatory requirements to maintain product stability.

Storage Conditions

Requirement	Specific Condition
Temperature	Store below 25 C
Container Protection	Keep the container tightly closed and in its original packaging
Child Safety	Keep out of the sight and reach of children

---

Shelf-Life and Disposal

Once the tube is first opened, the medicine must be discarded after 28 days (one month). Any unused or expired product must be disposed of following local regulatory requirements; it must not be thrown away via wastewater or general household waste.